Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
March 6, 2024Investor RSS News
- Insertion of a functional OTC gene through ARCUS in vivo gene editing may provide lasting clinical benefit for children with OTC deficiency who are in dire need for effective treatments - CTA…
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
March 1, 2024Investor RSS News
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 1, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in…
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
February 29, 2024Investor RSS News
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 29, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop…
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
February 20, 2024Investor RSS News
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 20, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene…
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness
February 14, 2024Investor RSS News
- Regulatory feedback and alignment from both U.S. and ex- U.S. regulators supports clinical development path for PBGENE-HBV - IND/CTA enabling studies with final clinical candidate underway for…
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
February 13, 2024Investor RSS News
- Dedicated Senior-Level Function will Enhance and Expand Existing Strategic IR Program DURHAM, N.C. --(BUSINESS WIRE)--Feb. 13, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene…
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
February 12, 2024Investor RSS News
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 12, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences to Effect a Reverse Stock Split
February 9, 2024Investor RSS News
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 9, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
January 9, 2024Investor RSS News
- Precision to Receive $17.5 Million in Upfront and Near-Term Payments with Potential for up to $288 Million in Other Development Milestone Payments - Upfront Cash and Near-Term Payments Expected to…
Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE
December 13, 2023Investor RSS News
- OTC Deficiency Gene Insertion Program, ECUR-506, Receives Clearance from Australian Therapeutic Goods Administration for Phase 1/2 Study DURHAM, N.C. --(BUSINESS WIRE)--Dec. 13, 2023-- Precision…
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
December 4, 2023Investor RSS News
- Publication validates unique ability of ARCUS genome editing to preferentially target and eliminate mutant m.3243G mitochondrial DNA (mtDNA) with high specificity - mitoARCUS efficiently shifted…
Precision BioSciences to Present at Hep-DART 2023
November 30, 2023Investor RSS News
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 30, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene…